What have clinical trials taught us about proarrhythmia?;Que nous ont enseigne les essais cliniques au sujet de la pro-arythmie?

Canadian Journal of Cardiology

Volumn 12, Issue SUPPL. B, 1996, Pages

  Skanes, Allan C ^a   Green, Martin S ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

Antiarrhythmic drugs; Arrhythmias; Myocardial infarction; Torsade de pointes

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ENCAINIDE; FLECAINIDE; MORACIZINE; QUINIDINE; SOTALOL;

CLINICAL TRIAL; CONFERENCE PAPER; DRUG FATALITY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HIGH RISK POPULATION; HOLTER MONITORING; HUMAN; HUMAN CELL; HUMAN TISSUE; META ANALYSIS; PATHOPHYSIOLOGY; REENTRY ARRHYTHMIA; SUDDEN DEATH; TORSADE DES POINTES;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; CLINICAL TRIALS; ELECTROCARDIOGRAPHY; HUMANS; MYOCARDIAL INFARCTION; TORSADES DE POINTES;

EID: 0029743148     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (39)

1. Kerr WG, Bender WL. Paroxysmal ventricular fibrillation with cardiac recovery in a case of auricular fibrillation and complete heart block while under quinidine sulfate therapy. Heart 1921;9:269-81.
2. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbity in patients receiving encainide, flecainide or placebo. N Engl J Med 1991;324:781-8.
3. Dessertenne F. La tachycardie ventriculaire a deux foyes oposes variables. Arch Mal Coeur 1966;59:263-72.
4. Nguyen FT, Scheinman MM, Seger J. Polymorphous ventricular tachycardia: clinical characterization, therapy, and the long QT interval. Circulation 1986;74:340-9.
5. Brachmann J, Scherlag BJ, Rosenstraukh LV, Lazzara R. Bradycardia-dependent triggered activity: relevance to drug-induced multiform ventricular tachycardia. Circulation 1983;68:846-56.
6. Roden DM, Huffman BF. Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers: relationship to potassium and cycle length. Circ Res 1985;56:857-67.
7. Dangman KH, Hoffman BF. In vivo and in vitro antiarrhythmic and arrhythmogenic effects of N-acetylprocainamide. J Pharmacol Exp Ther 1981;217:851-62.
8. Antzelevitch C, Sicouri S. Clinical relevance of cardiac arrhythmias generated by after depolarizations. J Am Coll Cardiol 1994;23:259-77.
9. Drouin E, Charpentter F, Gauthier C, et al. Evidence for the presence of M cells in the human ventricle. PACE 1993;5:824-37. (Abst)
10. Surawicz, B. Electrophysiologic substrate of torsade de pointes: dispersion of repolarization or early afterdepolamations? J Am Coll Cardiol 1989;14:172-84.
11. Statters DJ, Malik M, Ward DE, et al. QT dispersion: problems of methodology and clinical significance. J Cardiovasc Electrophysiol 1994;5:672-85.
12. Kuo CS, Munakata K, Reddy CP, et al. Characteristics and possible mechanism of ventricular arrhythmia dependent on the dispersion of action potential durations. Circulation 1983;67:1356-67.
13. Attwell D, Lee JA. A cellular basis for the primary long QT syndrome. Lancet 1988;i:1136.
14. Levine JH, Morganroth J, Kadish AH. Mechanisms and risk factors for proarrhvthmia with type la compared with le antiarrhythmic drug therapy. Circulation 1989;80:1063-9.
15. Hohnloser SH, Singh BN. Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications. J Cardiovasc Electrophysiol 1995;6:920-36.
16. Hohnloser SH, van de Loo A, Kalusche D, et al. Does sotalol-induced alteration in QT-dispersion predict drug effectiveness or proarrhythmic hazards? Circulation 1993;88:I-397A.
17. Hohnloser SH, Arendts W, Quart B. Incidence, type, and dose-dependence of proarrhythmic events during sotalol therapy in patients treated for sustained VT/VF. PACE 1992;15:173A.
18. Archibald DO, Quart B, Hardy S, et al. Torsade de pointes with sotalol: relationship of gender to risk, J Am Coll Cardiol 1994;23:279A.
19. Hohnloser SH, Klingenheben T, Singh BN. Amiodarone-associated proarrhythmic effects: A review with special reference to torsade de pointes tachycardia. Ann Intern Med 1994;121:529-35.
20. Burkart F, Pfisterer M, Kiowski W, et al. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study Of Infarct Survival (BASIS). Am Coll Cardiol 1990;16:1711-8.
21. Cairns JA, Connolly S, Gent M, et al. Post-myocardial infarction mortality in patients with ventricular premature depolarization: Canadian amiodarone myocardial infarction arrhythmia trial pilot study. Circulation 1991;84:550-7.
22. Ceremuzynski Y, Kleczar E, Krzeminska-Pakula M, et al. Effect of amiodarone on mortality after myocardial infarction. J Am Coll Cardiol 1992;20:1056-62.
23. Hamer AW, Arkles LB, Johns JA. Beneficial effects of low dose amiodarone in patients with congestive hear: failure: a placebo controlled trial. J Am Coll Cardiol 1989;14:1768-74.
24. Nicklas JM, McKenna WJ, Stewart RA, et al. Prospective double-blind, placebo-controlled trial of low-dose amiodarone in patients with severe heart failure and asymptomatic frequent ventricular ectopy. Am Heart J 1991;122:1016-21.
25. Doval HC, Nul DR, Grancelli HO, et al. Randormzed trial of low-dose amiodarone in severe congestive heart failure (GESICA). Lancet 1994;344:493-8.
26. Singh SN, Fletcher RD, Gross Fisher S, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995;333:77-82.
27. Takanaka C, Singh BN. Barium-induced nondriven action potentials as a model of triggered potentials from early depolarization as: significance of slow channel activity and differing effects of quinidine and amiodarone. J Am Coll Cardiol 1990;15:213-21.
28. Sager PT, Uppal P, Follmer C, et al. Frequency-dependent electrophysiologic effects of amiodarone in humans. Circulation 1993;88:1063-71.
29. Cui G, Sen L, Sager P, et al. Effects of sematilide, amiodarone and sotalol on QT dispersion Am J Cardiol 11994;74:896-900.
30. Hii JTY, Wyse DG, Gillis AM, et al. Precordial QT interval dispersion as a marker of torsade de pointes: disparate effects of class Ia antiarrhythmic drugs and amiodarone. Circulation 1992;86:1376-82.
31. Patterson E, Szabo B, Scherlag BJ, et al. Arrhythmogenic effects of antiarrhythmic drugs. In: Zipes D, Jalife J, eds. Cardiac Electrophysiology from Cell to Bedside. Philadelphia: WB Saunders, 1995:496-511.
32. Akiyama T, Pawitan Y, Greenberg H, et al. Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the cardiac arrhythmia suppression mal. Am J Cardiol 1991;68:1551-5.
33. Biggers JT Jr, Fleiss J, Steinman R, et al. Frequency domain measures of heart period variability and mortality after myocardial infarction. Circulation 1992;85:164-71.
34. Zuanetti G, Latini R, Neilson JM, et al. Heart rate variability in patients with ventricular arrhythmias: effect of antiarrhythmic drugs. J Am Coll Cardiol 1991;17:604-12.
35. Coplen SE, Antman EM, Berlin JA, et al. Efficacy and safety of quinidine therapy for the maintenance of sinus rhythm: a meta-analysis of randomized control trials. Circulation 1990;82:1106-16.
36. Waldo AL, Camm AJ, de Ruyter H. et al. Preliminary mortality results from the survival with oral d-sotalol (SWORD) trial. J Am Coll Cardiol 1995;25:15A.
37. Wyse DG, Morganroth J, Lidingham R, et al. New insights into the definition and meaning of proarrhythmia during initiation of antiarrhythmic drug therapy from the cardiac arrhythmia suppression trial and its pilot study. J Am Coll Cardiol 1994;23:1130-40.
38. The CAPS Investigators. The cardiac arrhythmia pilot study. Am J Cardiol 1986;57:91-5
39. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizme on survival after myocardial infarction. N Engl J Med 1992;32?227-33.